Welcome to our dedicated page for MiMedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on MiMedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a pioneer in the field of advanced wound care and therapeutic biologics. The company specializes in developing and distributing human placental tissue allografts utilizing patent-protected processes. With a cornerstone methodology known as the PURION® Process, MiMedx ensures the production of high-quality allografts via aseptic processing techniques and terminal sterilization.
Having supplied over two million allografts through direct and consignment shipments, MiMedx is a trusted name in the healthcare sector. The company’s product range includes EpiFix for external use and AmnioFix for internal applications, alongside other innovative products such as AmnioCord, AmnioFill, EpiBurn, and EpiCord. Additionally, MiMedx markets allografts for ophthalmic surgery and dental applications through third-party licenses.
MiMedx is dedicated to transforming wound care in sectors like burn treatment, surgical procedures, sports medicine, and orthopedics. By combining its extensive portfolio with strategic initiatives, such as its recent exclusive partnership with Regenity for a 510(k) cleared, bovine-derived collagen matrix, the company aims to enhance its competitive edge and expand its market reach.
Financially, MiMedx has shown impressive growth. For 2023, the company reported net sales of $321 million, reflecting a 20% increase from the previous year. Strategically, new credit facilities have been secured to bolster financial flexibility. The company expects low double-digit net sales growth for 2024 and an adjusted EBITDA margin exceeding 20%.
Despite facing regulatory challenges, such as the FDA’s stance on the AXIOFILL product, MiMedx continues to thrive. The company is actively engaging with the FDA while maintaining the product in the market. This resilience underscores MiMedx’s commitment to compliance and innovation in providing safe and effective products.
The company’s vision is to be the leading global provider of healing solutions through relentless innovation, aiming to restore quality of life for patients. For more information, visit www.mimedx.com.
MARIETTA, Ga., Dec. 22, 2021 – MiMedx Group, Inc. (Nasdaq: MDXG) announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 5:15 PM EST. Institutional investors can schedule virtual meetings with management through their J.P. Morgan representatives. A live webcast will be available on the Company’s website, with a replay accessible for 30 days post-presentation. MiMedx is a leader in placental biologics, focusing on non-healing wounds and musculoskeletal conditions.
MIMEDX Group, Inc. (MDXG) announced key insights during its virtual Investor Day, focusing on its KOA clinical program and robust commercial growth potential. The company anticipates initiating Phase 3 trials for its Knee Osteoarthritis candidate in 2022, with a Biologics License Application expected by late 2025. MIMEDX raised its adjusted net sales outlook for 2021 to $253-$258 million, surpassing previous estimates. The company's commercial strategy targets sustainable growth of 11-14% in several underpenetrated markets, driven by product innovation and global expansion initiatives.
MIMEDX (Nasdaq: MDXG) plans to host a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. CEO Timothy R. Wright will share insights from their knee osteoarthritis clinical study, highlighting significant outcomes in WOMAC scores with p-values below 0.05 at three months and below 0.01 at six months. The event will also cover growth strategies and advancements in their commercial business. Key speakers will include executives and third-party experts discussing the musculoskeletal pipeline and market opportunities. Registrations can be made using the access code ‘MDXG.’
MiMedx Group, Inc. (Nasdaq: MDXG) announced that Timothy R. Wright, CEO, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The presentation will be available on-demand starting November 22 at 10:00 AM ET on the Company’s website.
MiMedx specializes in regenerative medicine using amniotic tissue, aiming to address acute and chronic wounds, and has supplied over two million allografts to date.
MiMedx Group, Inc. (Nasdaq: MDXG) announced a peer-reviewed study demonstrating that its PURION® processed dHACM (EPIFIX®) provides a significantly lower risk for infection and scarring compared to traditional autologous tissue methods in Mohs micrographic surgeries. The study, involving 286 patients, revealed those using placental allografts were 12 times less likely to experience post-surgical infections and 19 times less likely to have unacceptable scarring. The findings validate the use of placental allografts as a safer reconstruction alternative, particularly for older patients with multiple skin cancer surgeries.
MiMedx Group reported third quarter 2021 net sales of $63.1 million, a slight decline from $64.3 million in 3Q20. Adjusted net sales of $62.8 million reflect a 13% increase in core portfolio sales year-over-year. The company recorded a net loss of $2.3 million, significantly less than $19.4 million in the previous year. Adjusted EBITDA was $6.8 million. The outlook for 2021 projects adjusted net sales between $245 million to $255 million, signaling potential growth in surgical applications and ongoing clinical efforts.
Marietta, Ga. — MiMedx Group (Nasdaq: MDXG) announced its participation in upcoming virtual investor conferences. CEO Timothy R. Wright, CFO Peter M. Carlson, and CCO Rohit Kashyap will engage in fireside chats at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 3:30 PM ET, and the Canaccord Genuity MedTech Forum on November 18, 2021, at 9:30 AM ET. Webcasts will be available via the company’s website. MiMedx specializes in regenerative medicine utilizing amniotic tissue for wound care and musculoskeletal conditions.
MIMEDX announced two peer-reviewed studies on micronized dehydrated human amnion chorion membrane (mdHACM) for treating osteoarthritis and tendinopathy. The studies reveal mdHACM's potential to regulate inflammatory processes and enhance tissue repair. The first study, published in Osteoarthritis and Cartilage Open, highlights mdHACM's chondroprotective effects by inhibiting key signaling pathways in chondrocytes. The second study in the Journal of Biomedical Materials Research, Part B, shows mdHACM diminishes inflammation and promotes healing in chronic tendon injuries, suggesting its role in regenerative medicine.
MiMedx Group, Inc. (Nasdaq: MDXG) will announce its third-quarter financial results for the period ending September 30, 2021, on November 2, 2021, after market close. A webcast and conference call are scheduled for November 3, 2021, at 8:30 AM ET to discuss these results. MiMedx specializes in regenerative medicine, particularly through the use of amniotic tissue. The company has supplied over two million allografts, focusing on treating acute and chronic non-healing wounds while developing a pipeline for degenerative musculoskeletal conditions.
Marietta, Ga. – MiMedx Group, Inc. (Nasdaq: MDXG) announced a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. The event will showcase the Company’s late-stage pipeline in musculoskeletal conditions and its advanced wound care business. Further registration details will be shared soon. A live webcast is accessible via the Company’s Investors section at www.mimedx.com, with a replay available post-event. MiMedx specializes in amniotic tissue for regenerative medicine, addressing severe non-healing wounds and musculoskeletal pain.
FAQ
What is the current stock price of MiMedx Group (MDXG)?
What is the market cap of MiMedx Group (MDXG)?
What does MiMedx Group, Inc. specialize in?
What are MiMedx's key products?
How has MiMedx performed financially in 2023?
What is the PURION® Process?
How does MiMedx handle regulatory challenges?
What new collaborations has MiMedx recently announced?
What is MiMedx's vision?
Where can I find more information about MiMedx?
What markets does MiMedx target?
Who can I contact for investor relations at MiMedx?
